Want to see ATAI full AI Analyst Report?
ATAI Stock Chart & Stats
$4.03
-$0.11(-6.29%)
At close: 4:00 PM EST
$4.03
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$2.81 - $7.22
Previous CloseN/A
Volume1.44M
Average Volume (3M)8.95M
Market Cap
$2.63B
Enterprise Value$1.04K
Total Cash (Recent Filing)$230.77M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 12, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding368,166,700
10 Day Avg. Volume8,686,742
30 Day Avg. Volume8,952,508
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.63Price Target Upside238.09% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$1.46M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BufferVery low debt and roughly $199M of equity versus $265M assets provide durable financial flexibility. This reduces refinancing risk, gives runway for clinical programs or partnerships, and supports strategic options (licensing, M&A) without immediate debt pressure.
High Gross Margins On Product EconomicsExceptionally high gross margins suggest strong unit economics for therapies if commercialized. Once regulatory and scale hurdles are passed, margins support sustainable profitability and attractive returns, assuming successful transition from R&D to commercial revenue.
Definitive Acquisition Agreement With Eli LillyA definitive buyout by a major pharma is a structural validation of ATAI's platform and lead programs. It materially de-risks financing needs, accelerates development/commercialization under Lilly, and crystallizes strategic value for long-term stakeholders.
Bears Say
Sustained Heavy Cash BurnPersistent negative operating and free cash flow indicates operations cannot self-fund development. Over months this drives reliance on external financing or strategic transactions, raising dilution and execution risk if financings are unfavorable or delayed.
Tiny And Declining Revenue BaseRevenue near $3.5M TTM and recent decline mean the company lacks commercial ballast. With negligible product sales, operating spending must be funded externally, making the business structurally dependent on milestone/licensing events or capital markets.
Deep Operating And Net LossesExtremely negative margins reflect R&D and SG&A vastly outpacing revenue. If losses persist, equity dilution and shareholder value erosion follow unless programs succeed or strategic exits occur, creating a durable execution and funding risk profile.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $2.81 and its highest was $7.22 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $2.63B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 25 days.
How were Atai Beckley N.V.’s earnings last quarter?
Atai Beckley N.V. released its earnings results on May 12, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.027.
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.11.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 368,166,700 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Atai Beckley N.V. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went up 2.723%.
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.63 (238.09% Upside)
$13.63 (238.09% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 88%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $442.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Company Description
Atai Beckley N.V.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
ATAI Stock 12 Month Forecast
Average Price Target
$13.63
▲(238.09% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
32.37% Insiders
3.56% Mutual Funds
0.05% Other Institutional Investors
52.28% Public Companies and Individual Investors